PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.16%
R&D growth while AGEN reduces spending. John Neff would investigate strategic advantage.
23.98%
G&A growth while AGEN reduces overhead. John Neff would investigate operational differences.
No Data
No Data available this quarter, please select a different quarter.
7.46%
Other expenses growth while AGEN reduces costs. John Neff would investigate differences.
15.26%
Operating expenses growth while AGEN reduces costs. John Neff would investigate differences.
15.26%
Total costs growth while AGEN reduces costs. John Neff would investigate differences.
-36.68%
Interest expense reduction while AGEN shows 1.72% growth. Joel Greenblatt would examine advantage.
7.46%
D&A growth above 1.5x AGEN's 2.49%. Michael Burry would check for excessive investment.
-50.67%
EBITDA decline while AGEN shows 20.16% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-15.26%
Operating income decline while AGEN shows 15.59% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-81.62%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-50.43%
Pre-tax income decline while AGEN shows 10.88% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-36.68%
Tax expense reduction while AGEN shows 65.05% growth. Joel Greenblatt would examine advantage.
-50.43%
Net income decline while AGEN shows 10.88% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-43.14%
EPS decline while AGEN shows 11.19% growth. Joel Greenblatt would examine position.
-43.14%
Diluted EPS decline while AGEN shows 11.19% growth. Joel Greenblatt would examine position.
5.01%
Share count reduction below 50% of AGEN's 0.32%. Michael Burry would check for concerns.
5.01%
Diluted share reduction below 50% of AGEN's 0.32%. Michael Burry would check for concerns.